Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lansion Biotechnology

Request full access

Specialized in research and development, production, sell, services of in vitro diagnostic reagents and devices

ChinaFounded 2016Biotech & Life Sciences

About Lansion Biotechnology

Lansion Biotechnology Co., Ltd., founded in 2016 by Jeffery Chen, is a biotechnology firm headquartered in Nanjing, China, specializing in the in-vitro diagnostic (IVD) sector. The company operates as both a manufacturer and trading company, focusing on the research, development, production, and sale of IVD reagents and devices. Since its inception, Lansionbio has secured significant financial backing, raising a total of $14.2 million over five funding rounds, with its latest being a Series D round in September 2022. Notable investors include CICC, Matrix Partners China, and Dynamic Balance Capital.

The company's business model is centered on providing comprehensive solutions for on-site rapid detection to medical units and families through its integrated multi-platform Point-of-Care Testing (POCT) workstation. This approach positions Lansionbio as a key enterprise in China's laboratory medicine industry. Revenue is generated through the sale of its diagnostic products and services to a global client base, with primary markets in Africa, Northern Europe, and the Middle East. Lansionbio's product portfolio is extensive, featuring a range of analyzers and test kits built upon its core technology platforms: microfluidics, immunochromatography, and molecular diagnosis. Products include fluorescence immunoassay analyzers, PCR instruments, and various reagent test kits for detecting cardiovascular diseases, tumor markers, infectious diseases like COVID-19, and more. A significant milestone was the active involvement in the global COVID-19 pandemic response, with its related products receiving CE certification and being exported to over 50 countries.

Lansionbio has established a significant operational footprint, including a 20,000-square-meter R&D center and a 4,000-square-meter aseptic purification workshop compliant with GMP standards. The company holds ISO13485 certification, underscoring its commitment to quality management for medical devices. The core research and development team consists of professionals from well-known research institutions and bio-pharmaceutical companies. With between 301 and 500 employees, the company reports an annual revenue between US$5 million and US$10 million.

Source: Dealroom company data

At a glance

Status
Operational
Employees
56
Open positions
1
Dealroom signal
57.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES D✓Equity / VC Sep 2022 $14M $55M Undisclosed ↗
SERIES C✓Equity / VC Nov 2019 $14M $56M Matrix Partners China —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Lansion Biotechnology website traffic

Latest recorded traffic for Lansion Biotechnology is 260 monthly website visits, down 66.7% over the last three months. Lansion Biotechnology's team grew 0% over the past year.

Latest monthly visits260 3-month web change-66.7% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Lansion Biotechnology in its local ecosystem

Live from Dealroom

The Lansion Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇳 China92%
🇸🇬 Singapore4%
🇺🇸 United States4%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lansion Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lansion Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.